Tianshan Pharmaceutical

Xinjiang Tianshan Pharmaceutical Industrial Co., Ltd. is a specialized pharmaceutical company headquartered in Urumqi, China, primarily focused on the research, development, and large-scale manufacturing of licorice-derived medications. Founded in 1986, the company is recognized as a global leader in the production of glycyrrhizic acid and its various derivatives, such as diammonium glycyrrhizinate and monoammonium glycyrrhizinate. These compounds are widely utilized in the treatment of chronic hepatitis, liver dysfunction, and various inflammatory conditions. In 2015, the company was acquired by Grand Pharmaceutical Group Limited, which integrated Tianshan's specialized production capabilities into its broader respiratory and gastroenterology segments. Tianshan Pharmaceutical operates several GMP-certified manufacturing lines and exports its active pharmaceutical ingredients (APIs) and finished products to international markets, including Japan and Southeast Asia.